New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
Expected Next-Generation Drugs Under Development in Relation to Voiding Symptoms.
ÌÇÐÄ´«Ã½
Expected Next-Generation Drugs Under Development in Relation to Voiding Symptoms. International neurourology journal Chung, K. J., Chung, B. I. 2017; 21 (2): 97–101Abstract
New drug development is a high-risk venture, but if successful, will bring great revenues to those willing to accept the risk. In the field of urology, in particular for lower urinary tract symptoms (LUTS), the recent successful landing of drugs (e.g., mirabegron, botulinum toxin A, and tadalafil) has resulted in increased interest in new drug development. Benign prostatic hyperplasia and overactive bladder syndrome, representative LUTS diseases, are attractive targets because of their prevalence and market size in the field of urology. Additionally, the awareness about new stream of ÌÇÐÄ´«Ã½ is very important not only because of the market size and economic factors, but also because to keep steady attention to these ÌÇÐÄ´«Ã½ for the ÌÇÐÄ´«Ã½er's. We have reviewed a selection of new drugs currently under development for the treatment of the two aforementioned diseases and hope to offer urologists an overview of the current situation and future directions in the field of urology.
View details for
View details for